Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ALNY
- CUSIP: 02043Q10
- Web: www.alnylam.com
Capitalization:- Market Cap: $7.4689 billion
- Outstanding Shares: 91,733,000
Average Prices:- 50 Day Moving Avg: $80.83
- 200 Day Moving Avg: $63.46
- 52 Week Range: $31.38 - $86.92
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -15.13
- P/E Growth: -0.33
Sales & Book Value:- Annual Revenue: $66 million
- Price / Sales: 113.17
- Book Value: $12.25 per share
- Price / Book: 6.65
Profitability:- EBIDTA: ($436,510,000.00)
- Net Margins: -670.81%
- Return on Equity: -45.53%
- Return on Assets: -34.43%
Debt:- Debt-to-Equity Ratio: 0.13%
- Current Ratio: 8.84%
- Quick Ratio: 8.84%
Misc:- Average Volume: 940,292 shs.
- Beta: 2.95
- Short Ratio: 11.01
Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($1.34) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.22) by $0.12. The firm earned $15.93 million during the quarter, compared to analysts' expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business's revenue for the quarter was up 82.9% compared to the same quarter last year. During the same period last year, the company earned ($1.05) earnings per share. View Alnylam Pharmaceuticals' Earnings History.
When will Alnylam Pharmaceuticals make its next earnings announcement?
Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?
18 analysts have issued 12-month target prices for Alnylam Pharmaceuticals' shares. Their predictions range from $50.00 to $126.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $83.44 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.
What are analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. Chardan Capital analysts commented, "We believe far and away the least likely scenario is that patisiran fails to demonstrate efficacy in APOLLO, considering that, as discussed above, the clinical effect of TTR silencing has been de- risked by top-line results from NEURO-TTR. A significant disconnect between the APOLLO and NEURO-TTR studies is, in our view, only possible if, as discussed in the 9 January 2017 company note, the differences in the patient population between the phase II OLE and APOLLO study (APOLLO has more advanced patients than the phase II OLE) leads to a slower rate of mNIS+7 increase in the placebo arm than is expected in natural history since, to our understanding, the NEURO-TTR patient population is likely somewhere between the phase II OLE and APOLLO populations." (8/10/2017)
- 2. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)
- 3. Needham & Company LLC analysts commented, "Alnylam reported additional results from Phase 2 OLE trial of fitusiran in Hemophilia A and B pts w/ and w/ o inhibitors. Efficacy w/ respect to Annualized Bleeding Rate and target antithrombin knockdown remains favorable and consistent w/ prior data from this program. Alnylam reported several asymptomatic >3X ALT elevations, one of which led to a discontinuation. Mgmt believes these events may be tied to HCV infection, highlighting that all events occurred in pts w/ history of HCV and most significant events were observed in pts w/ active infection. Alnylam is excluding Hemophilia pts w/ active HCV infection from Phase 3 trials. Data from Phase 1 trial published today are not consistent with a dose-dependent impact on ALT elevation. We continue to have a favorable view towards the program given current overall profile (safety, efficacy, and convenience), but acknowledge a level of risk around liver enzymes, which will probably not be clarified until Phase 3 completed." (7/10/2017)
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), ICON PLC (ICLR), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), FibroGen (FGEN), Portola Pharmaceuticals (PTLA), Sage Therapeutics (SAGE) and INC Research Holdings (INCR).
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Michael W. Bonney, Independent Chairman of the Board
- Barry E. Greene, President
- John M. Maraganore Ph.D., Chief Executive Officer, Director
- Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer
- Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President
- Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development
- Laurie B. Keating, Senior Vice President, General Counsel, Secretary
- Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
- Theresa Heggie, Senior Vice President, Head of Europe and Canada
- Peter F. Smith Ph.D., Senior Vice President - Early Development
Who owns Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.92%), Dodge & Cox (10.66%), Vanguard Group Inc. (7.45%), BlackRock Inc. (6.02%), Baillie Gifford & Co. (3.98%) and State Street Corp (2.11%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., State Street Corp, Dodge & Cox, Balyasny Asset Management LLC, Rockefeller Financial Services Inc., Wells Fargo & Company MN, Tekla Capital Management LLC and Pictet Asset Management Ltd.. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Janus Henderson Group PLC, BlackRock Inc., TIAA CREF Investment Management LLC, PDT Partners LLC, Farallon Capital Management LLC and Broadfin Capital LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy Alnylam Pharmaceuticals stock?
Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $81.42.
MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 5 Hold Ratings, 12 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.61) |
| Consensus Price Target: | $83.44 (2.49% upside) |
Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/11/2017 | Credit Suisse Group | Reiterated Rating | Buy | $96.00 | Low |  |
| 8/10/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $47.00 -> $56.00 | Medium | |
| 8/10/2017 | Chardan Capital | Reiterated Rating | Buy | $131.00 -> $124.00 | Medium | |
| 8/10/2017 | Morgan Stanley | Boost Price Target | Equal Weight | $46.00 -> $50.00 | Medium | |
| 8/10/2017 | Barclays PLC | Boost Price Target | Equal Weight | $50.00 -> $70.00 | High | |
| 7/27/2017 | Sanford C. Bernstein | Initiated Coverage | Outperform | $99.00 | High | |
| 7/17/2017 | Ladenburg Thalmann Financial Services | Set Price Target | Buy -> Buy | $80.00 -> $90.00 | Low | |
| 7/11/2017 | Cowen and Company | Reiterated Rating | Buy | $100.00 | Low | |
| 7/10/2017 | Needham & Company LLC | Reiterated Rating | Buy | $98.00 | Low | |
| 6/26/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | | N/A | |
| 6/22/2017 | Jefferies Group LLC | Reiterated Rating | Buy -> Buy | $102.00 | Low | |
| 6/21/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $116.00 -> $126.00 | Low | |
| 6/2/2017 | Janney Montgomery Scott | Initiated Coverage | Underperform -> Sell | $69.70 -> $67.00 | Low | |
| 5/17/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $44.00 -> $64.00 | Medium | |
| 5/17/2017 | Leerink Swann | Reiterated Rating | Market Perform | $53.00 -> $67.00 | High | |
| 4/17/2017 | BMO Capital Markets | Initiated Coverage | Outperform | $73.00 | Medium | |
| 3/20/2017 | FBR & Co | Reiterated Rating | Buy | | High | |
| 2/3/2017 | JMP Securities | Set Price Target | Buy | $69.00 | N/A | |
| 11/26/2015 | S&P Equity Research | Downgrade | Buy -> Hold | | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ ALNY)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($1.26) | | | | | N/A | |
| 8/9/2017 | Q2 2017 | ($1.22) | ($1.34) | $23.86 million | $15.93 million | View | Listen | |
| 5/5/2017 | Q1 2017 | ($1.22) | ($1.25) | $22.91 million | $19.00 million | View | N/A | |
| 2/8/2017 | Q416 | ($1.34) | ($1.32) | $10.66 million | $17.50 million | View | Listen | |
| 11/2/2016 | Q316 | ($1.14) | ($1.21) | $9.14 million | $13.70 million | View | N/A | |
| 8/4/2016 | Q216 | ($1.24) | ($1.05) | $8.09 million | $8.70 million | View | Listen | |
| 5/2/2016 | Q116 | ($1.05) | ($1.21) | $7.79 million | $7.30 million | View | Listen | |
| 2/11/2016 | Q415 | ($0.96) | ($1.07) | $9.59 million | $7.60 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.91) | ($0.91) | $7.55 million | $6.30 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.75) | ($0.85) | $12.64 million | $8.69 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.65) | ($0.62) | $15.40 million | $18.51 million | View | N/A | |
| 2/12/2015 | Q414 | ($0.66) | ($0.28) | $13.10 million | $24.00 million | View | N/A | |
| 11/5/2014 | Q314 | ($0.63) | ($0.58) | $8.93 million | $11.00 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.54) | ($0.63) | $9.36 million | $7.30 million | View | N/A | |
| 5/8/2014 | Q114 | ($1.18) | ($0.39) | $10.80 million | $8.30 million | View | N/A | |
| 2/19/2014 | Q413 | ($0.45) | ($0.51) | $9.98 million | $10.80 million | View | N/A | |
| 11/6/2013 | Q313 | ($0.39) | ($0.48) | $8.64 million | $9.00 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.35) | ($0.29) | $8.99 million | $8.70 million | View | Listen | |
| 5/6/2013 | Q1 2013 | ($0.29) | ($0.15) | $15.56 million | $18.60 million | View | Listen | |
| 2/7/2013 | Q4 2012 | ($1.45) | ($1.20) | $15.82 million | $8.50 million | View | Listen | |
| 11/5/2012 | Q312 | ($0.32) | ($0.31) | $17.30 million | $16.80 million | View | N/A | |
| 8/6/2012 | | ($0.21) | ($0.25) | | | View | N/A | |
| 5/3/2012 | | ($0.35) | ($0.25) | | | View | N/A | |
| 2/9/2012 | | ($0.33) | ($0.33) | | | View | N/A | |
| 11/1/2011 | | ($0.35) | ($0.31) | | | View | N/A | |
| 8/1/2011 | | ($0.36) | ($0.33) | | | View | N/A | |
| 5/2/2011 | | ($0.30) | ($0.38) | | | View | N/A | |
| 2/17/2011 | | ($0.35) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)2017 EPS Consensus Estimate: ($4.93)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($1.36) | ($1.30) | ($1.33) |
| Q2 2017 | 2 | ($1.20) | ($1.15) | ($1.18) |
| Q3 2017 | 2 | ($1.25) | ($1.18) | ($1.22) |
| Q4 2017 | 2 | ($1.32) | ($1.10) | ($1.21) |
(Data provided by Zacks Investment Research)
Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ:ALNY)Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 88.99%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/31/2017 | Sanofi | Major Shareholder | Buy | 297,501 | $71.87 | $21,381,396.87 | |
| 5/30/2017 | Laurie Keating | SVP | Buy | 11,500 | $65.35 | $751,525.00 | |
| 5/23/2017 | Akshay Vaishnaw | EVP | Sell | 11,000 | $75.00 | $825,000.00 | |
| 5/16/2017 | Michael Mason | VP | Sell | 9,375 | $70.00 | $656,250.00 | |
| 5/15/2017 | Akshay Vaishnaw | SVP | Sell | 43,750 | $65.00 | $2,843,750.00 | |
| 1/25/2017 | Philip A Sharp | Director | Sell | 15,000 | $37.95 | $569,250.00 | |
| 1/18/2017 | Philip A Sharp | Director | Sell | 15,000 | $37.83 | $567,450.00 | |
| 11/30/2016 | Akshay Vaishnaw | CMO | Sell | 29,165 | $44.99 | $1,312,133.35 | |
| 10/13/2016 | David E I Pyott | Director | Buy | 27,900 | $37.00 | $1,032,300.00 | |
| 7/20/2016 | John Maraganore | CEO | Sell | 30,151 | $64.69 | $1,950,468.19 | |
| 4/20/2016 | John Maraganore | CEO | Sell | 30,151 | $67.46 | $2,033,986.46 | |
| 3/9/2016 | Michael W Bonney | Director | Buy | 2,000 | $58.36 | $116,720.00 | |
| 2/22/2016 | David-Alexandre C Gros | SVP | Buy | 1,000 | $62.75 | $62,750.00 | |
| 2/1/2016 | Sanofi | Major Shareholder | Buy | 205,030 | $69.75 | $14,300,842.50 | |
| 1/20/2016 | John Maraganore | CEO | Sell | 30,152 | $71.78 | $2,164,310.56 | |
| 12/4/2015 | Philip A. Sharp | Director | Sell | 30,000 | $109.00 | $3,270,000.00 | |
| 12/2/2015 | John Maraganore | CEO | Sell | 58,689 | $104.87 | $6,154,715.43 | |
| 11/20/2015 | John Maraganore | CEO | Sell | 58,690 | $102.88 | $6,038,027.20 | |
| 11/12/2015 | Kevin P. Starr | Director | Sell | 75,000 | $103.89 | $7,791,750.00 | |
| 6/16/2015 | Akshay Vaishnaw | CMO | Sell | 8,750 | $128.83 | $1,127,262.50 | |
| 5/12/2015 | Michael W Bonney | Director | Buy | 2,000 | $112.16 | $224,320.00 | |
| 4/21/2015 | Paul Schimmel | Director | Sell | 10,000 | $130.02 | $1,300,200.00 | |
| 3/19/2015 | Dennis A Ausiello | Director | Sell | 5,000 | $120.00 | $600,000.00 | |
| 3/17/2015 | Akshay Vaishnaw | CMO | Sell | 8,750 | $116.86 | $1,022,525.00 | |
| 1/29/2015 | Sanofi | Major Shareholder | Buy | 97,118 | $95.00 | $9,226,210.00 | |
| 1/26/2015 | John Maraganore | CEO | Buy | 10,000 | $95.00 | $950,000.00 | |
| 1/26/2015 | Steven M Paul | Director | Buy | 1,000 | $95.00 | $95,000.00 | |
| 12/19/2014 | Barry E Greene | COO | Sell | 11,200 | $100.00 | $1,120,000.00 | |
| 12/16/2014 | Akshay Vaishnaw | EVP | Sell | 10,626 | $93.60 | $994,593.60 | |
| 12/15/2014 | Michael Mason | VP | Sell | 22,162 | $97.50 | $2,160,795.00 | |
| 11/18/2014 | Laurence Reid | SVP | Sell | 10,000 | $90.67 | $906,700.00 | |
| 11/17/2014 | Barry E Greene | COO | Sell | 33,200 | $89.63 | $2,975,716.00 | |
| 10/28/2014 | Paul Schimmel | Director | Sell | 15,000 | $95.00 | $1,425,000.00 | |
| 10/22/2014 | Dennis A Ausiello | Director | Sell | 5,000 | $90.00 | $450,000.00 | |
| 10/13/2014 | Philip A Sharp | Director | Sell | 110,000 | $85.00 | $9,350,000.00 | |
| 9/25/2014 | Kevin P Starr | Director | Sell | 90,000 | $78.09 | $7,028,100.00 | |
| 9/24/2014 | Kevin P Starr | Director | Sell | 45,000 | $79.08 | $3,558,600.00 | |
| 9/18/2014 | John Maraganore | CEO | Sell | 113,668 | $77.71 | $8,833,140.28 | |
| 9/16/2014 | Akshay Vaishnaw | EVP | Sell | 10,625 | $72.04 | $765,425.00 | |
| 8/18/2014 | Laurence Reid | SVP | Sell | 13,500 | $67.34 | $909,090.00 | |
| 6/26/2014 | John Maraganore | CEO | Sell | 113,668 | $65.45 | $7,439,570.60 | |
| 6/17/2014 | Akshay Vaishnaw | EVP | Sell | 10,625 | $69.82 | $741,837.50 | |
| 5/21/2014 | John Clarke | Director | Sell | 35,000 | $53.80 | $1,883,000.00 | |
| 5/19/2014 | Laurence Reid | SVP | Sell | 13,500 | $57.83 | $780,705.00 | |
| 5/15/2014 | John Maraganore | CEO | Sell | 113,668 | $56.73 | $6,448,385.64 | |
| 3/25/2014 | Sanofi | major shareholder | Buy | 344,448 | $66.88 | $23,036,682.24 | |
| 3/18/2014 | Akshay Vaishnaw | EVP | Sell | 32,769 | $73.95 | $2,423,267.55 | |
| 2/19/2014 | Laurence Reid | SVP | Sell | 20,400 | $80.06 | $1,633,224.00 | |
| 1/24/2014 | Akshay Vaishnaw | EVP | Sell | 7,890 | $85.75 | $676,567.50 | |
| 1/13/2014 | Paul Schimmel | Director | Sell | 15,000 | $85.36 | $1,280,400.00 | |
| 12/20/2013 | Paul Schimmel | Director | Sell | 15,000 | $65.00 | $975,000.00 | |
| 12/17/2013 | Akshay Vaishnaw | EVP | Sell | 33,480 | $60.72 | $2,032,905.60 | |
| 10/22/2013 | Paul Schimmel | Director | Sell | 15,000 | $60.00 | $900,000.00 | |
| 9/11/2013 | John Maraganore | CEO | Sell | 58,947 | $55.50 | $3,271,558.50 | |
| 9/10/2013 | Akshay Vaishnaw | EVP | Sell | 6,250 | $57.48 | $359,250.00 | |
| 8/14/2013 | John Maraganore | CEO | Sell | 60,000 | $48.97 | $2,938,200.00 | |
| 7/12/2013 | Michael Mason | VP | Sell | 14,200 | $50.00 | $710,000.00 | |
| 7/10/2013 | John Maraganore | CEO | Sell | 60,000 | $37.11 | $2,226,600.00 | |
| 7/1/2013 | Michael Mason | VP | Sell | 27,000 | $32.00 | $864,000.00 | |
| 6/17/2013 | Michael Mason | VP | Sell | 23,625 | $29.93 | $707,096.25 | |
| 6/11/2013 | Akshay Vaishnaw | EVP | Sell | 15,000 | $31.08 | $466,200.00 | |
| 5/28/2013 | Barry E Greene | COO | Sell | 22,822 | $30.00 | $684,660.00 | |
| 5/28/2013 | Laurence Reid | SVP | Sell | 5,000 | $30.00 | $150,000.00 | |
| 3/26/2013 | Kevin P Starr | Director | Sell | 52,631 | $23.49 | $1,236,302.19 | |
| 1/22/2013 | Philip A Sharp | Director | Buy | 4,967 | $20.13 | $99,985.71 | |
(Data available from 1/1/2013 forward)
Headline Trends for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
| Source: |
|
| Date | Headline |
|---|
 | Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ...
www.nasdaq.com - August 18 at 3:53 PM |
 | Alnylam Pharmaceuticals, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 18 at 3:52 PM |
 | BidaskClub Downgrades Alnylam Pharmaceuticals, Inc. (ALNY) to Buy
www.americanbankingnews.com - August 17 at 12:08 AM |
 | Merck CEO quits presidential council after Charlottesville violence ‘as a matter of personal conscience,’ and Trump attacks him
www.marketwatch.com - August 15 at 4:47 PM |
| Alnylam Shoots For The Moon With Apollo - Seeking Alpha
seekingalpha.com - August 14 at 4:05 PM |
 | Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
www.fool.com - August 14 at 2:55 PM |
| Alnylam Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($1.18) Per Share, Leerink Swann Forecasts (NASDAQ:ALNY)
www.americanbankingnews.com - August 14 at 3:52 AM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Credit Suisse Group
www.americanbankingnews.com - August 12 at 5:42 PM |
| Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss - Nasdaq
www.nasdaq.com - August 12 at 3:34 PM |
 | EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q2 Earnings Report
www.rttnews.com - August 11 at 4:11 PM |
| Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs
www.fool.com - August 11 at 4:11 PM |
 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
finance.yahoo.com - August 11 at 4:11 PM |
| Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : August 11, 2017
finance.yahoo.com - August 11 at 4:11 PM |
| Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss
finance.yahoo.com - August 10 at 10:13 PM |
| Alnylam Pharmaceuticals' (NASDAQ:ALNY) "Buy" Rating Reiterated at Chardan Capital
www.americanbankingnews.com - August 10 at 7:02 PM |
| Alnylam Pharmaceuticals (ALNY) Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 5:10 PM |
| Edited Transcript of ALNY earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 5:10 PM |
| Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - August 10 at 5:02 PM |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target Raised to $0.00 at Barclays PLC
www.americanbankingnews.com - August 10 at 3:03 PM |
| After 10 months, Alnylam still can't explain patient trial deaths
finance.yahoo.com - August 10 at 1:59 AM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 12:50 AM |
 | Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity - Business Wire (press release)
www.businesswire.com - August 9 at 8:59 PM |
| Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity
finance.yahoo.com - August 9 at 8:58 PM |
| Alnylam reports 2Q loss
finance.yahoo.com - August 9 at 8:58 PM |
| Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season - Nasdaq
www.nasdaq.com - August 8 at 8:25 PM |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 8 at 7:04 PM |
| Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season
finance.yahoo.com - August 8 at 3:21 PM |
| Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
finance.yahoo.com - August 8 at 3:21 PM |
| 3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
finance.yahoo.com - August 8 at 3:21 PM |
| Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered
finance.yahoo.com - August 8 at 3:21 PM |
| Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
finance.yahoo.com - August 8 at 3:21 PM |
| Leerink Swann Comments on Alnylam Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:ALNY)
www.americanbankingnews.com - August 7 at 7:04 AM |
| Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Quarterly Sales of $22.22 Million
www.americanbankingnews.com - August 6 at 7:14 AM |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - August 5 at 9:56 PM |
| Zacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Earnings of -$1.20 Per Share
www.americanbankingnews.com - August 4 at 8:26 PM |
| Alnylam Pharmaceuticals (ALNY) Update On Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary TransthyretinMediated (hATTR)
seekingalpha.com - August 4 at 4:08 PM |
| Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 1 at 9:47 PM |
| Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 4:46 PM |
| Alnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series
finance.yahoo.com - July 27 at 3:21 PM |
| Somerville Kurt F Buys JM Smucker Co, Analog Devices Inc, Fortive Corp, Sells NXP ... - Nasdaq
www.nasdaq.com - July 26 at 3:53 PM |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:14 AM |
| ALNY Crosses Above Average Analyst Target
www.nasdaq.com - July 21 at 5:23 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 4:04 PM |
| Zacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $22.22 Million
www.americanbankingnews.com - July 15 at 8:19 AM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 14 at 6:44 PM |
| -$1.20 Earnings Per Share Expected for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) This Quarter
www.americanbankingnews.com - July 13 at 2:16 PM |
| Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth
finance.yahoo.com - July 12 at 9:19 PM |
| Alnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation
seekingalpha.com - July 11 at 9:59 PM |
| Alnylam Buckles Down On A Belt Of Rare Diseases - Seeking Alpha
seekingalpha.com - July 11 at 4:59 PM |
| Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma
finance.yahoo.com - July 11 at 4:59 PM |
Alnylam Pharmaceuticals (ALNY) Chart for Sunday, August, 20, 2017
